Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imlifidase - Hansa Biopharma

Drug Profile

Imlifidase - Hansa Biopharma

Alternative Names: EnzE programme - Hansa Biopharma AB; Enzyme-based antibody enhancement programme - Hansa Biopharma AB; HMed-IdeS; IDEFIRIX; Idefirix; IdeS; IgG-degrading enzyme of Streptococcus pyogenes; IgG-endopeptidase; Mac-1; Streptococcal cysteine proteinase

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hansa Medical AB
  • Developer Asklepios BioPharmaceutical; Hansa Biopharma AB; Sarepta Therapeutics
  • Class Antibacterials; Antineoplastics; Antirheumatics; Bacterial proteins; Endopeptidases; Immunotherapies
  • Mechanism of Action Immunoglobulin inhibitors; Immunostimulants; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anti-glomerular basement membrane disease; Guillain-Barre syndrome; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase III Anti-glomerular basement membrane disease
  • Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Guillain-Barre syndrome; Thrombotic thrombocytopenic purpura
  • Phase I Duchenne muscular dystrophy
  • Preclinical Autoimmune disorders; Crigler-Najjar syndrome; Glycogen storage disease type II; Limb girdle muscular dystrophies
  • No development reported Cancer
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 27 Feb 2024 Hansa Biopharma completes phase-II trial for Guillain-Barre syndrome in United Kingdom, France, and Netherlands (IV) (NCT03943589)
  • 06 Jan 2024 Preregistration for Renal transplant rejection (Prevention) in Middle East, North Africa (IV)
  • 06 Jan 2024 Hansa Biopharma anticipates completes enrolment in the phase III trial for Anti-glomerular basement membrane disease (anti-GBM disease) in 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top